Results 41 to 50 of about 4,681 (114)

Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era. [PDF]

Nutr Clin Pract
Vavrina K, Griffin TB, Jones AM, Schindler T, Bui TN, Sankararaman S.   +5 more
europepmc   +1 more source

Changes in Sleep in Children and Adults with Cystic Fibrosis and Primary Ciliary Dyskinesia over Time and after CFTR Modulator Therapy. [PDF]

J Clin Med, 2023
Cohen-Cymberknoh M, Lehavi M, Gileles-Hillel A, Atia O, Breuer O, Reiter J.   +5 more
europepmc   +1 more source

Theratyping as a tool to guide clinical decision-making in patients with suspected cystic fibrosis and variants currently ineligible for CFTR modulator therapy. [PDF]

Respir Med
Gannon RM, Wright BA, Bettis BA, Teresi ME, Fischer AJ, Weiner RL, Peña T, Hornick DB, Thornell IM, Rehman T, Pezzulo AA.   +10 more
europepmc   +1 more source

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass. [PDF]

Front Pharmacol, 2023
Mouzaki M, Dupuis A, Avolio J, Griffin K, Ratjen F, Tullis E, Gonska T.   +6 more
europepmc   +1 more source

WS13.2 Novel F508del-CFTR corrector that complements other CFTR modulators

Journal of Cystic Fibrosis, 2016
J.P. Miller, L. Drew, C.M. Bastos, D.J. Parks, O. Green, B. McEwan, N. Patel, S. Aghamohammadzadeh, A. Villella, K.A. Giuliano, K.A. Longo, M. Ivarsson, B. Munoz, H. Mehmet   +13 more
openaire   +1 more source

Antisense oligonucleotide targeting the E3 ligase RFFL potentiates CFTR modulator efficacy in CF primary bronchial epithelial cells. [PDF]

Mol Ther Nucleic Acids
Hinata D, Kai Y, Fukuda R, Kamada Y, Kasahara Y, Sasaki K, Yoshida T, Obika S, Inoue T, Okiyoneda T.   +9 more
europepmc   +1 more source

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis. [PDF]

ERJ Open Res, 2022
Muilwijk D, Zomer-van Ommen DD, Gulmans VAM, Eijkemans MJC, van der Ent CK, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: .   +5 more
europepmc   +1 more source

CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. [PDF]

Nat Commun
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK.   +16 more
europepmc   +1 more source

Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis. [PDF]

Eur Arch Otorhinolaryngol, 2023
Bode SFN, Rapp H, Lienert N, Appel H, Fabricius D.   +4 more
europepmc   +1 more source

Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies. [PDF]

Children (Basel)
García-Pérez-de-Sevilla G, Blanco Velasco Á, Yvert T, Sanz-Santiago V, Tirado AM, López Neyra A, de Manuel C, Ruiz Valbuena M, Pérez-Ruiz M.   +8 more
europepmc   +1 more source